国际医学
(000516)
| 流通市值：112.67亿 | | | 总市值：114.41亿 |
| 流通股本：22.05亿 | | | 总股本：22.39亿 |
| 报告期 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,034,307,690.46 | 997,091,245.37 | 4,815,466,752.34 | 3,606,256,924.42 |
| 营业收入 | 2,034,307,690.46 | 997,091,245.37 | 4,815,466,752.34 | 3,606,256,924.42 |
| 二、营业总成本 | 2,279,057,237.69 | 1,144,868,275.73 | 5,180,946,550.96 | 3,892,721,588.98 |
| 营业成本 | 1,875,680,998.18 | 945,151,168.84 | 4,360,364,605.85 | 3,274,876,374.7 |
| 税金及附加 | 31,930,143.98 | 15,985,577.62 | 63,357,153.1 | 47,322,428.77 |
| 销售费用 | 12,906,646.69 | 1,432,439.49 | 36,764,036.4 | 19,025,093.8 |
| 管理费用 | 276,375,329.41 | 140,249,920.11 | 540,139,717.86 | 415,587,071.07 |
| 研发费用 | 3,933,910.53 | 2,000,084.54 | 6,990,751.27 | 5,715,774.18 |
| 财务费用 | 78,230,208.9 | 40,049,085.13 | 173,330,286.48 | 130,194,846.46 |
| 其中:利息费用 | 74,534,722.28 | 37,894,863.77 | 173,353,108.43 | 130,933,373 |
| 其中:利息收入 | 1,799,808.67 | 406,557.16 | 7,956,159.16 | 6,228,860.17 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,320,448.33 | -7,713,784.02 | 25,370,529.61 | -7,902,134.7 |
| 加:投资收益 | 20,940,436.87 | 21,175,420.18 | -1,600,542.89 | -1,003,915.95 |
| 资产处置收益 | - | - | 1,655,587.15 | 303,928.99 |
| 信用减值损失(新) | 7,608,278.07 | 3,552,550.89 | -8,075,933.67 | -3,543,284.95 |
| 其他收益 | 2,217,058.32 | 1,870,607.93 | 5,947,834.42 | 15,203,655.54 |
| 四、营业利润 | -211,663,325.64 | -128,892,235.38 | -342,182,324 | -283,406,415.63 |
| 加:营业外收入 | 571,131.57 | 440,353.95 | 636,268.16 | 617,062.66 |
| 减:营业外支出 | 2,039,546.9 | 2,215,394.82 | 3,098,006.02 | 694,555.7 |
| 五、利润总额 | -213,131,740.97 | -130,667,276.25 | -344,644,061.86 | -283,483,908.67 |
| 减:所得税费用 | 5,181,229.26 | 2,292,710.54 | 20,495,657.19 | 10,788,863.23 |
| 六、净利润 | -218,312,970.23 | -132,959,986.79 | -365,139,719.05 | -294,272,771.9 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -218,312,970.23 | -132,959,986.79 | -365,139,719.05 | -294,272,771.9 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -164,961,830.49 | -106,353,858.88 | -254,128,508.13 | -212,108,983.83 |
| 少数股东损益 | -53,351,139.74 | -26,606,127.91 | -111,011,210.92 | -82,163,788.07 |
| 扣除非经常损益后的净利润 | -189,033,816.89 | -119,746,738.91 | -286,928,104.43 | -219,532,355.14 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.07 | -0.05 | -0.11 | -0.1 |
| (二)稀释每股收益 | -0.07 | -0.05 | -0.11 | -0.1 |
| 九、综合收益总额 | -218,312,970.23 | -132,959,986.79 | -365,139,719.05 | -294,272,771.9 |
| 归属于母公司股东的综合收益总额 | -164,961,830.49 | -106,353,858.88 | -254,128,508.13 | -212,108,983.83 |
| 归属于少数股东的综合收益总额 | -53,351,139.74 | -26,606,127.91 | -111,011,210.92 | -82,163,788.07 |
| 公告日期 | 2025-08-22 | 2025-04-23 | 2025-04-23 | 2024-10-25 |
| 审计意见(境内) | | | 标准无保留意见 | |